

Immunotherapy in MSI-H CRC

Shereef Elsamany Oncology Centre, KAMC, Makkah

CRC subtyping consortium – 2015




Guinney J, Dienstmann R et al. Nat Med 2015




Guinney J, Dienstmann R et al. Nat Med 2015


MisMatch Repair system (MMR)




Deficient MMR system



Altered apoptose, cell cycle related gened \rightarrow MSI CRC carcinogenesis



Guinney et al, Nature 2015



How to test MSI-status?


• IHC of MLH1, MSH2, MSH6, PMS2 expression

• Molecular testing

• Both


Molecular testing: Genotyping 5 microsatellites allows the characterization of microsatellite tumor instability

- If at least 2 of the 5 microsatellites are unstable, the tumor phenotype is "MSI-high" or dMMR
- I Immunohistochemical testing: Tumor tissue can be checked for expression of DNA mismatch repair protein MLH1, MSH2, MSH6 or PMS1.
- Loss of expression indicates that the corresponding gene is not being appropriately expressed and suggests the existence of a mutation or epigenetic silencing




MSI: loss of MLH1 in tumor cells

Immunohistochemistry Stable tumour (MSS): 4 MMR proteins expressed



Immunohistochemistry Instable tumour(MSI): extinction of MMR proteins



personna I casel F. Bibeau

*MisMatch Repair

How to test MSI-status ?

• IHC of MLH1, MSH2, MSH6, PMS2 expression


• Molecular testing of microsatellites mutation



MSI-H in hereditary tumours only ??

• Yes (Hereditary non-polyposis colorectal cancer)





Microsatellite instability context

MSI and hMLH1 loss

Sporadic cancer (15%)

Hypermethylation MLH1 promotor

BRAF mutation

Elderly patient

Lynch syndrome (2%)

Absent

Absent


Young patient

MSI-H in hereditary tumours only ??



• No, mostly sporadic cases

MISMATCH REPAIR DEFICIENCY ACROSS CANCERS




Who should be tested for MSI


• All GI patients

• Selected patients


• At time of diagnosis

• After failure of 1-2 lines





Rankin Oncologist 2016



Guinney J, Dienstmann R et al. Nat Med 2015

Who should be tested for MSI

• All GI patients

• Selected patients: RT, mucinous, BRAF mut

At time of diagnosis

• After failure of 1-2 lines

Chemotherapy in MSI-H patients


VOLUME 28 - NUMBER 20 - JULY 10 2010

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer 1027 patients included in trials demonstrating the effect of FU in adjuvant settings


MSI + (dMMR) 185 pts (18%)



Dan Sargent et al, JCO 2010

www.pathologie-universitaetsmedizin-dresden.de

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer



en.de

Pembrolizumab in MSI-H CRC

Anti-PD1 in CRC

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring,
A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower,
A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg,
A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood,
N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish,
J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, and L.A. Diaz, Jr.

Le et al, NEJM 2015

MSI vs MSS



FDA approval pembrolizumab MSI tumors

FDA News Release

FDA approves first cancer treatment for any solid tumor with a specific genetic feature

FDA Approves Mercks KEYTRUDA (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer

Pembrolizumab Approved for MSI-H or Mismatch Repair Deficient Tumors

Table 23: MSI-H Trials

Študy	Design and Patient Population	Number of patients	MSI-HidMMR testing	Dese	Prior therapy
KEYNOTE-016 NCT01076511	 prospective, investigator- initiated 6 sites patients with CRC and other tumors 	28 CRC 30 non-CRC	local PCR or IHC	10 mg/kg every 2 weeks	CRC: ≥ 2 prior regimens Non-CRC: ≥1 prior regimen
KEYNOTE-164 NCT02460198	prospective international multi- center GRC	61	local PCR or IHC	200 mg exery 3 weeks	Prior fluoropyrimidine, oxaliplatin, and irinotecan +/- anti- VEGF/EGFR mAb
KEYNOTE-012 NCT01848834	 retrospectively identified patients with PD-L1-positive gastric, bladder, or triple- negative breast cancer 	6	central PCR	10 mg/kg every 2 weeks	21 prior regimen.
KEYNOTE-028 NCT02054806	 retrospectively identified patients with PD-L1-positive esophageal, bikary, breast, endometrial, or CRC 	6	central PCR	10 mg/kg every 2 weeks	≥1 prior regimen
KEYNOTE-158 NCT02628067	 prospective international multi- center enrolment of patients with MSI-HidMMR non-CRC retrospectively identified patients who were enrolled in specific rare tumor non-CRC cohorts 	19	local PCR or IHC (central PCR for patients in rare tumor non-CRC cohorts)	200 mg exery 3 weeks	≥1 prior regimen
Total		149			

CRC = colorectal cancer

PCR = polymerase chain reaction

IHC = immunohistochemistry

Package insert

Pembrolizumab Approved for MSI-H or Mismatch Repair Deficient Tumors

New (H2)	N	Objective r n (%)	esponse rate 95% Cl	DOR range (months)
CRC	90	32 (36%)	(26%, 46%)	(1.6+, 22.7+)
Non-CRC	59	27 (46%)	(33%, 59%)	(1.9+, 22.1+)
Endometrial cancer	14	5 (36%)	(13%, 65%)	(4.2+, 17.3+)
Biliary cancer	- 11	3 (27%)	(6%, 61%)	(11.6+, 19.6+)
Gastric or GE junction cancer	9	5 (56%)	(21%, 86%)	(5.8+, 22.1+)
Pancreatic cancer	6	5 (83%)	(36%, 100%)	(2.6+, 9.2+)
Small intestinal cancer	8	3 (38%)	(9%, 76%)	(1.9+, 9,1+)
Breast cancer	2	PR, PR		(7.6, 15.9)
Prostate cancer	2	PR, SD		9.8+
Bladder cancer	1	NE		
Esophageal cancer	1	PR		18.2+
Sarcoma	1	PD	1	507772
Thyroid cancer	1	NE		
Retroperitoneal adenocarcinoma	1	PR		7.5+
Small cell lung cancer	1	CR		8.9+
Renal cell cancer	1	PD		

Table 25: Response by Tumor Type

CR = complete response

PR = partial response

SD = stable disease

PD = progressive disease

NE = not evaluable

Package insert

Nivolumab in CRC

Nivolumab ± Ipilimumab in Treatment of Patients With Metastatic Colorectal Cancer With and Without High Microsatellite Instability: CheckMate 142 Interim Results


Michael Overman,¹ Scott Kopetz,¹ Ray McDermott,² Joseph Leach,³ Sara Lonardi,⁴ Heinz-Josef Lenz,⁵ Michael Morse,⁶ Jayesh Desai,⁷ Andrew Hill,⁸ Michael Axelson,⁹ Rebecca A. Moss,⁹ Chen-Sheng Lin,⁹ Monica Goldberg,⁹ Thierry Andre¹⁰

¹MD Anderson Cancer Center, Houston, TX, USA; ²St Vincent's University Hospital, Dublin, Ireland; ³Allina Health System, Minneapolis, MN, USA; ⁴Istituto Oncologico Veneto IOV-IRCSS, Padova, Italy; ⁵USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA; ⁶Duke University Office of Research Administration, Durham, NC, USA; ⁷Royal Melbourne Hospital, Victoria, Australia; ⁸Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia; ⁹Bristol-Myers Squibb, Princeton, NJ, USA; ¹⁰Hopital Saint Antoine, Paris, France

PRESENTED AT: ASCO ANNUAL MEETING '16 Slides are the property of the author. Permission required for reuse.

Presented By Michael Overman at 2016 ASCO Annual Meeting

Best Reduction in Target Lesion Size in Patients With MSI-H




15

Nivolumab + Ipilimumab MSI

		N3 (n=70)	N3 + I1 (n=30)
ORR, n (%) ^ь		12 (25.5)	9 (33.3)
	CR	0	0
	SD	14 (29.8%)	14 (51.9%)
	PD	17 (36.2%)	3 (11.1%)
	ND/NR	4 (8.5%)	1 (3.7%)


Investigator-Assessed PFS in Patients With MSI-H

Nivolumab ± Ipilimumab in Metastatic CRC



Presented By Michael Overman at 2016 ASCO Annual Meeting

OS in Patients With MSI-H *Nivolumab* ± *Ipilimumab in Metastatic CRC*



Presented By Michael Overman at 2016 ASCO Annual Meeting

Can we use immune therapy in MSS?






• Yes for combination IO.

Author		Drug	N	ORR
Le et al	MSS CRC	Pembrolizumab	18	0%
Overman et al	MSS CRC	Nivolumab + ipilimumab	20	5%
Chung et al	Refractory CRC	Tremelimumab	49	2%
Topialan et al	Refractory CRC	Nivolumab	19	0%

Ineffective in MSS tumors

Lee et al, N. Engl. J. Med. 2015;372:2509–2520 Overman et al, J. Clin. Oncol. 2016;34:3501. Chung et al, J Clin Oncol. 2010 Jul 20; 28(21):3485-90. Topalian et al, N. Engl. J. Med. 2012;366:2443–2454.


Cotezo TRIAL



- Stratified by tumor extended RAS status and time since diagnosis of first metastasis
- MSI-H capped at approximately 5%
- At least 180 patients with extended RAS-mutant tumors to be enrolled

Effect of MEK-I on T-cells and TME


- MEKi: intratumoral T cell accumulation + MHC Class I upregulation
- MEK inhibition and anti-PDL1 are synergistic in xenograft models



Bendell et al, ASCO 2016; Ebert et al. Immunity 2016


Cobimetinib + Atezolizumab

	KRAS MT CRC	All CRC pts
	N=20	N=23
ORR	<mark>20%</mark>	17%
CR	0	0
PR	20%	17%
SD	20%	22%
PD	50%	52%
NE	10%	9%
mPFS (m)	2.3 (1.8-9.5)	2.3 (1.8-9.5)
mOS (m)	NE (6.5-NE)	NE (6.5-NE)




*Confirmed per RECIST v1.1. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease. Efficacy-evaluable patients. 2 patients missing or unevaluable are not included. Data cut-off February 12, 2016.

COBIMETINIB + ATEZOLIZUMAB IN MCRC



- 7 patients (8% [95% CI: 3, 16]) experienced PR (confirmed per RECIST v1.1)
 - 4 patients had MSS and 1 patient had MSI-low mCRC; the remaining 2 had unknown MSI status^b
- The DCR was 31% (DCR defined as PR + SD ≥ 6 weeks)

COBIMETINIB + ATEZOLIZUMAB IN MCRC



Phase III COTEZO trial – cobimetinib/atezolizumab vs regorafenib vs atezolizumab


Can we use immune therapy in MSS?






• Yes for combination IO.


Other potential targets



SPECTAcolor: Folprecht ESMO 2016, abst 4580



Trastuzumab/Lapatinib Responses by HER2 IHC Score



Conclusion

- Testing for MSI: timing and patient selection should be based on available resources and facilities
- MSI-H CRC: Pembro/nivo in previously treated patients
- MSI-H tumours: Pembro in previously treated patients

Conclusion

• One size does not fit all

• If you pick the target, use the right tool

• Immunotherapy in MSI-H tumours is an example

